Prakt. lékáren. 2015; 11(5): 160-163

Polymyalgia rheumatica and giant cell arteritis

Martina Bělobrádková1, Jan Tomš1, Zdeněk Bělobrádek2, Tomáš Soukup1
1 II. interní gastroenterologická klinika, Lékařská fakulta UK a Fakultní nemocnice Hradec Králové
2 Radiologická klinika, Lékařská fakulta UK a Fakultní nemocnice Hradec Králové

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are the autoimmune diseases occuring after 50 years of age with maximum

around seventy – eighty years of age. Their common apearance indicates, that both diseases have an unknown etiopathogenetic denominator

until now. On the other hand their symptoms and prognosis are completely different. PMR symptoms are painfull stiffness in

the pelvic, schoulder girdle and nuchal muscles. GCA is often accompanied by headaches caused by affection of blood vessels in the area

of artery carotis comunis and interna, nodular enlargement of the temporal artery branches is often seen. Usual and feared sign of GCA is

sudden blindness as a result of vascular oclussion of vessels causing optic nerve ischemia. Immunopatologic inflammation is the essence

of both diseases and manifests by high value of reactans of acute phase (Erythrocyte Sedimentation Rate, C-reactive protein levels). There

is no specific diagnostic blood or plasma test available yet. The diagnosis of PMR lies in clinical picture and exclusion of other diferential

options. The diagnosis of GCA is primarily based on the typical histological picture of arterial wall. Nowadays the imaging modalities

are very helpful for diagnosis, for example positron emission tomography in the combination with the computer tomography. The gold

standard in the treatment of both diseases is long-term (at least 1 or 2 years) administration of glucocorticoids with gradual reduction

of dosage. Of course this treatment is accompained by a variety of commonly known advers effects. In both cases there is a typical

significant improvement of health condition very soon after therapy initiation. PMR therapy is consisted of prednison 15–20 mg daily,

the inital treatment of GCA is 2–3× higher dosage of corticosteroids. In the case of imminent threat of blindness the prompt high-dose

intravenous administration of corticosteroids is essential.

Keywords: polymyalgia rheumatica, giant cell arteritis, glukocorticoids

Published: October 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bělobrádková M, Tomš J, Bělobrádek Z, Soukup T. Polymyalgia rheumatica and giant cell arteritis. Praktické lékárenství. 2015;11(5):160-163.
Download citation

References

  1. Pavelka K. Polymyalgia rheumatica - diagnostika a léčba. Postgraduální medicína 2011; 13(5): 551-557.
  2. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61(10): 1454-1461. Go to original source... Go to PubMed...
  3. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41(5): 778-799. Go to original source...
  4. Porsman VA. Arthritis in old age. Proc II Congr Europ Rheum (Barcelona). 1951; : 481-497.
  5. Rovenský J, Imrich R, Bošák V, et al. Polymyalgia rheumatica a obrovskobuněčná arteriitida. Postgraduální medicína 2004; 6(1): 81-87.
  6. Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 1998; 41(7): 1221-1226. Go to original source...
  7. Cantini F, Salvarani C, Olivieri I, et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 2001; 28(5): 1049-1055. Go to PubMed...
  8. Dasgupta B, Cimmino MA, Kremers HM, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64(4): 943-954. Go to original source... Go to PubMed...
  9. Van der Geest KS, Abdulahad WH, Rutgers A, et al. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. Rheumatology 2015. Go to original source...
  10. Cutolo M, Cimmino MA, Sulli A. Polymyalgia rheumatica vs late-onset rheumatoid arthritis. Rheumatology (Oxford) 2009; 48(2): 93-95. Go to original source... Go to PubMed...
  11. Muller S, Hider S, Belcher J, et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Annals of the rheumatic diseases 2013; 73(10): 1769-1773. Go to original source... Go to PubMed...
  12. Dejaco Ch, et al. Proposal ACR-EULAR guidelines in treatment of polymyalgia rheumatica, ACR Annual Meeting Boston 2014, abstract.
  13. Caylor TL, Perkins A. Recognition and management of polymyalgia rheumatica and giant cell arteritis. American family physician 2013; 88(10): 676-684. Go to PubMed...
  14. Ness T, Bley,TA, Schmidt WA, et al. The diagnosis and treatment of giant cell arteritis. Deutsches Ärzteblatt international 2013; 110(21): 376. Go to original source... Go to PubMed...
  15. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33(8): 1122-1128. Go to original source... Go to PubMed...
  16. Horton BT, Magath TB, Brown GE. Arteritis of the temporal vessels: previously undescribed form. Arch Int Med 1934; 53(3): 400-409. Go to original source...
  17. Gilmour JR. Giant-cell chronic arteritis. J Pathol Bacteriol. 1941; 53(2): 263-277. Go to original source...
  18. Nesher G, Berkun Y, Mates M, et al. Low dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis & Rheumatism 2004; 50(4): 1332-1337. Go to original source... Go to PubMed...
  19. Ponte C, Rodrigues AF, O'Neill L, Luqmani RA. Giant cell arteritis: Current treatment and management. World Journal of Clinical Cases 2015; WJCC, 3(6): 484. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.